Physician profile
Robert S Knepshield
NPI 1700026051
$2,355.29
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $594 · 2021: $1,199 · 2024: $20.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $475.79 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $324.90 | 2019-2021 | |
| Novo Nordisk INC | $260.29 | 2019-2021 | |
| Lilly USA, LLC | $223.42 | 2019-2021 | |
| Amgen INC. | $196.97 | 2019-2021 | |
| Lucid Diagnostics INC. | $93.28 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $85.17 | 2021 | |
| Allergan, INC. | $72.20 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $67.04 | 2019-2021 | |
| Eisai INC. | $64.51 | 2021 | |
| Pfizer INC. | $59.13 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $47.23 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $43.65 | 2019 | |
| Genentech USA, INC. | $42.34 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.48 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $28.92 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.91 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.57 | 2020-2021 | |
| Astellas Pharma US INC | $22.30 | 2021 | |
| Hologic Sales and Service, LLC | $20.93 | 2021 | |
| Exact Sciences Corporation | $20.30 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $19.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.55 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.77 | 2021 | |
| Dermira, INC. | $16.99 | 2020 | |
| Shire North American Group INC | $16.62 | 2019 | |
| Amneal Pharmaceuticals LLC | $13.38 | 2019 | |
| Amarin Pharma, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Knepshield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.